Journal Article10.1111/TRF.13089
Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease.
Naomi L.C. Luban,Naomi L.C. Luban,Edward C.C. Wong,Edward C.C. Wong,Rodolfo Henrich Lobo,Philippe Pary,Sarah Duke +6 more
35
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.
Brian W. McCrindle,Anne H. Rowley,Jane W. Newburger,Jane C. Burns,Anne F. Bolger,Michael H. Gewitz,Annette L. Baker,Mary Anne Jackson,Masato Takahashi,Pinak B. Shah,Tohru Kobayashi,Mei-Hwan Wu,Tsutomu Saji,Elfriede Pahl +13 more
TL;DR: These recommendations provide updated and best evidence-based guidance to healthcare providers who diagnose and manage Kawasaki disease, but clinical decision making should be individualized to specific patient circumstances.
3.1K
Diagnosis and management of Kawasaki disease.
TL;DR: It is prudent to consider childhood Kawasaki disease to be a potential risk factor for coronary disease, especially in atherosclerosis-prone Western societies.
153
Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach.
Lani Lieberman,Lani Lieberman,Andreas Greinacher,Michael F. Murphy,James B. Bussel,Tamam Bakchoul,Stacy Corke,Mette Kjaer,Jens Kjeldsen-Kragh,Jens Kjeldsen-Kragh,Gerald Bertrand,Dick Oepkes,Jillian M. Baker,Heather Hume,Edwin Massey,Cécile Kaplan,Donald M. Arnold,Shoma Baidya,Greg Ryan,Greg Ryan,Helen Savoia,Denise Landry,Nadine Shehata,Nadine Shehata,Nadine Shehata +24 more
TL;DR: FNAIT studies that optimize antenatal and postnatal management, develop risk stratification algorithms to guide management and standardize laboratory testing to identify high risk pregnancies are needed.
84
Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012
TL;DR: Dose levels and total IVIG dose administered are examined to identify possible patient and product risk factors for intravenous immune globulin (IVIG)‐associated hemolysis, a recognized side effect of IG therapy.
37
Hepcidin-Induced Iron Deficiency Is Related to Transient Anemia and Hypoferremia in Kawasaki Disease Patients.
Ying-Hsien Huang,Ying-Hsien Huang,Ho-Chang Kuo,Ho-Chang Kuo,Fu-Chen Huang,Fu-Chen Huang,Hong-Ren Yu,Hong-Ren Yu,Kai-Sheng Hsieh,Kai-Sheng Hsieh,Ya-Ling Yang,Jiunn-Ming Sheen,Sung-Chou Li,Hsing-Chun Kuo +13 more
TL;DR: Findings provide a longitudinal study of hemoglobin changes and among the first evidence that hepcidin induces transient anemia and hypoferremia during KD’s acute inflammatory phase.
35
References
Diagnosis, treatment, and long-term management of Kawasaki disease: A statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association
Jane W. Newburger,Masato Takahashi,Michael A. Gerber,Michael H. Gewitz,Lloyd Y. Tani,Jane C. Burns,Stanford T. Shulman,Ann F. Bolger,Patricia Ferrieri,Robert S. Baltimore,Walter R. Wilson,Larry M. Baddour,Matthew E. Levison,Thomas J. Pallasch,Donald A. Falace,Kathryn A. Taubert +15 more
TL;DR: A new algorithm is proposed to aid clinicians in deciding which children with fever for ≥5 days and ≤4 classic criteria should undergo electrocardiography, receive intravenous gamma globulin (IVIG) treatment, or both for Kawasaki disease.
1.6K
•Book
Red Book: 2012 Report of the Committee on Infectious Diseases
Larry K. Pickering
- 01 Jun 2012
TL;DR: The new 29th edition's timely, topical coverage spans immunization...school health...blood safety...STIs...drug therapy...antimicrobial prophylaxis...diseases from anthrax and smallpox to West Nile virus, tuberculosis, influenza, and pneumococcal infections...plus much more.
843
Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology
Jordan S. Orange,Elham Hossny,Catherine R. Weiler,Mark Ballow,Melvin Berger,Francisco A. Bonilla,Rebecca H. Buckley,Javier Chinen,Yehia El-Gamal,Bruce Mazer,Robert P. Nelson,Dhavalkumar D. Patel,Elizabeth Secord,Ricardo U. Sorensen,Richard L. Wasserman,Charlotte Cunningham-Rundles +15 more
TL;DR: In this review, the evidence underlying a wide variety of IGIV uses is evaluated and specific recommendations on the basis of these data are made.
650
Intravenous immunoglobulin for Guillain-Barré syndrome
TL;DR: Although there are no adequate comparisons with placebo, intravenous immunoglobulin hastens recovery from Guillain-Barré syndrome as much as plasma exchange.
Management of Kawasaki disease
TL;DR: Recent advances in the understanding of KD pathogenesis and therapeutics are summarized, and an approach for managing KD patients in the UK in the light of these advances is provided.
278